Bionano Genomics Inc (NASDAQ:BNGO)
| 1.09 Delayed Data As of Mar 22 |  -0.05 / -4.39%Today’s Change | 1.06 Today|||52-Week Range 4.35 | -25.34% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $355.2M |
Company Description
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Contact Information
Bionano Genomics, Inc. 9540 Towne Centre Drive San Diego California 92121 |
Employees
Shareholders
| Individual stakeholders | 3.59% |
| Mutual fund holders | 16.20% |
| Other institutional | 11.80% |
Top Executives
| Robert Erik Holmlin | President, CEO, Secretary & Director |
| Mark Oldakowski | Chief Operating Officer |
| Christopher Stewart | Chief Financial & Accounting Officer |
| Alka Chaubey | Chief Medical Officer |
| Shroff Hema | Vice President & Regulatory Affairs |
